Literature DB >> 26105953

AB-CHMINACA, AB-PINACA, and FUBIMINA: Affinity and Potency of Novel Synthetic Cannabinoids in Producing Δ9-Tetrahydrocannabinol-Like Effects in Mice.

Jenny L Wiley1, Julie A Marusich2, Timothy W Lefever2, Kateland R Antonazzo2, Michael T Wallgren2, Ricardo A Cortes2, Purvi R Patel2, Megan Grabenauer2, Katherine N Moore2, Brian F Thomas1.   

Abstract

Diversion of synthetic cannabinoids for abuse began in the early 2000s. Despite legislation banning compounds currently on the drug market, illicit manufacturers continue to release new compounds for recreational use. This study examined new synthetic cannabinoids, AB-CHMINACA (N-[1-amino-3-methyl-oxobutan-2-yl]-1-[cyclohexylmethyl]-1H-indazole-3-carboxamide), AB-PINACA [N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide], and FUBIMINA [(1-(5-fluoropentyl)-1H-benzo[d]imadazol-2-yl)(naphthalen-1-yl)methanone], with the hypothesis that these compounds, like those before them, would be highly susceptible to abuse. Cannabinoids were examined in vitro for binding and activation of CB1 receptors, and in vivo for pharmacological effects in mice and in Δ(9)-tetrahydrocannabinol (Δ(9)-THC) discrimination. AB-CHMINACA, AB-PINACA, and FUBIMINA bound to and activated CB1 and CB2 receptors, and produced locomotor suppression, antinociception, hypothermia, and catalepsy. Furthermore, these compounds, along with JWH-018 [1-pentyl-3-(1-naphthoyl)indole], CP47,497 [rel-5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol], and WIN55,212-2 ([(3R)-2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenyl-methanone, monomethanesulfonate), substituted for Δ(9)-THC in Δ(9)-THC discrimination. Rank order of potency correlated with CB1 receptor-binding affinity, and all three compounds were full agonists in [(35)S]GTPγS binding, as compared with the partial agonist Δ(9)-THC. Indeed, AB-CHMINACA and AB-PINACA exhibited higher efficacy than most known full agonists of the CB1 receptor. Preliminary analysis of urinary metabolites of the compounds revealed the expected hydroxylation. AB-PINACA and AB-CHMINACA are of potential interest as research tools due to their unique chemical structures and high CB1 receptor efficacies. Further studies on these chemicals are likely to include research on understanding cannabinoid receptors and other components of the endocannabinoid system that underlie the abuse of synthetic cannabinoids.
Copyright © 2015 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26105953      PMCID: PMC4538877          DOI: 10.1124/jpet.115.225326

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  27 in total

1.  A novel precursor ion discovery method on a hybrid quadrupole orthogonal acceleration time-of-flight (Q-TOF) mass spectrometer for studying protein phosphorylation.

Authors:  R H Bateman; R Carruthers; J B Hoyes; C Jones; J I Langridge; A Millar; J P C Vissers
Journal:  J Am Soc Mass Spectrom       Date:  2002-07       Impact factor: 3.109

2.  Pentylindole/Pentylindazole Synthetic Cannabinoids and Their 5-Fluoro Analogs Produce Different Primary Metabolites: Metabolite Profiling for AB-PINACA and 5F-AB-PINACA.

Authors:  Ariane Wohlfarth; Marisol S Castaneto; Mingshe Zhu; Shaokun Pang; Karl B Scheidweiler; Robert Kronstrand; Marilyn A Huestis
Journal:  AAPS J       Date:  2015-02-28       Impact factor: 4.009

3.  Schedules of controlled substances: temporary placement of three synthetic cannabinoids into schedule I. Final order.

Authors: 
Journal:  Fed Regist       Date:  2015-01-30

4.  Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs.

Authors:  B R Martin; D R Compton; B F Thomas; W R Prescott; P J Little; R K Razdan; M R Johnson; L S Melvin; R Mechoulam; S J Ward
Journal:  Pharmacol Biochem Behav       Date:  1991-11       Impact factor: 3.533

5.  Determination and characterization of a cannabinoid receptor in rat brain.

Authors:  W A Devane; F A Dysarz; M R Johnson; L S Melvin; A C Howlett
Journal:  Mol Pharmacol       Date:  1988-11       Impact factor: 4.436

6.  Aminoalkylindole analogs: cannabimimetic activity of a class of compounds structurally distinct from delta 9-tetrahydrocannabinol.

Authors:  D R Compton; L H Gold; S J Ward; R L Balster; B R Martin
Journal:  J Pharmacol Exp Ther       Date:  1992-12       Impact factor: 4.030

7.  Isolation and structure of a brain constituent that binds to the cannabinoid receptor.

Authors:  W A Devane; L Hanus; A Breuer; R G Pertwee; L A Stevenson; G Griffin; D Gibson; A Mandelbaum; A Etinger; R Mechoulam
Journal:  Science       Date:  1992-12-18       Impact factor: 47.728

8.  Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities.

Authors:  D R Compton; K C Rice; B R De Costa; R K Razdan; L S Melvin; M R Johnson; B R Martin
Journal:  J Pharmacol Exp Ther       Date:  1993-04       Impact factor: 4.030

9.  A comparison of the discriminative stimulus properties of delta 9-tetrahydrocannabinol and CP 55,940 in rats and rhesus monkeys.

Authors:  L H Gold; R L Balster; R L Barrett; D T Britt; B R Martin
Journal:  J Pharmacol Exp Ther       Date:  1992-08       Impact factor: 4.030

10.  Pharmacological profile of a series of bicyclic cannabinoid analogs: classification as cannabimimetic agents.

Authors:  D R Compton; M R Johnson; L S Melvin; B R Martin
Journal:  J Pharmacol Exp Ther       Date:  1992-01       Impact factor: 4.030

View more
  30 in total

1.  Thermolytic Degradation of Synthetic Cannabinoids: Chemical Exposures and Pharmacological Consequences.

Authors:  Brian F Thomas; Timothy W Lefever; Ricardo A Cortes; Megan Grabenauer; Alexander L Kovach; Anderson O Cox; Purvi R Patel; Gerald T Pollard; Julie A Marusich; Richard C Kevin; Thomas F Gamage; Jenny L Wiley
Journal:  J Pharmacol Exp Ther       Date:  2017-01-13       Impact factor: 4.030

2.  Delivery of nicotine aerosol to mice via a modified electronic cigarette device.

Authors:  Timothy W Lefever; Youn O K Lee; Alexander L Kovach; Melanie A R Silinski; Julie A Marusich; Brian F Thomas; Jenny L Wiley
Journal:  Drug Alcohol Depend       Date:  2017-01-18       Impact factor: 4.492

3.  In vitro determination of the efficacy of illicit synthetic cannabinoids at CB1 receptors.

Authors:  Shivani Sachdev; Kiran Vemuri; Samuel D Banister; Mitchell Longworth; Michael Kassiou; Marina Santiago; Alexandros Makriyannis; Mark Connor
Journal:  Br J Pharmacol       Date:  2019-12-10       Impact factor: 8.739

Review 4.  Synthetic Pot: Not Your Grandfather's Marijuana.

Authors:  Benjamin M Ford; Sherrica Tai; William E Fantegrossi; Paul L Prather
Journal:  Trends Pharmacol Sci       Date:  2017-02-02       Impact factor: 14.819

5.  Methodology for controlled administration of smoked synthetic cannabinoids JWH-018 and JWH-073.

Authors:  Ziva D Cooper; Justin L Poklis; Fei Liu
Journal:  Neuropharmacology       Date:  2017-11-14       Impact factor: 5.250

6.  Evaluation of first generation synthetic cannabinoids on binding at non-cannabinoid receptors and in a battery of in vivo assays in mice.

Authors:  Jenny L Wiley; Timothy W Lefever; Julie A Marusich; Megan Grabenauer; Katherine N Moore; John W Huffman; Brian F Thomas
Journal:  Neuropharmacology       Date:  2016-07-20       Impact factor: 5.250

7.  Pharmacological characterization of repeated administration of the first generation abused synthetic cannabinoid CP47,497.

Authors:  Travis W Grim; Kimberly L Samano; Bogna Ignatowska-Jankowska; Qing Tao; Laura J Sim-Selly; Dana E Selley; Laura E Wise; Alphonse Poklis; Aron H Lichtman
Journal:  J Basic Clin Physiol Pharmacol       Date:  2016-05-01

8.  Increases in synthetic cannabinoids-related harms: Results from a longitudinal web-based content analysis.

Authors:  Francois R Lamy; Raminta Daniulaityte; Ramzi W Nahhas; Monica J Barratt; Alan G Smith; Amit Sheth; Silvia S Martins; Edward W Boyer; Robert G Carlson
Journal:  Int J Drug Policy       Date:  2017-06-01

9.  Molecular and Behavioral Pharmacological Characterization of Abused Synthetic Cannabinoids MMB- and MDMB-FUBINACA, MN-18, NNEI, CUMYL-PICA, and 5-Fluoro-CUMYL-PICA.

Authors:  Thomas F Gamage; Charlotte E Farquhar; Timothy W Lefever; Julie A Marusich; Richard C Kevin; Iain S McGregor; Jenny L Wiley; Brian F Thomas
Journal:  J Pharmacol Exp Ther       Date:  2018-03-16       Impact factor: 4.030

10.  In vitro and in vivo pharmacological evaluation of the synthetic cannabinoid receptor agonist EG-018.

Authors:  Thomas F Gamage; Daniel G Barrus; Richard C Kevin; David B Finlay; Timothy W Lefever; Purvi R Patel; Megan A Grabenauer; Michelle Glass; Iain S McGregor; Jenny L Wiley; Brian F Thomas
Journal:  Pharmacol Biochem Behav       Date:  2020-04-02       Impact factor: 3.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.